New investigational drug offers potential treatment option for lung cancer patients

[News]

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

More... (http://www.news-medical.net/news/20131021/New-investigational-drug-offers-potential-treatment-option-for-lung-cancer-patients.aspx)